´╗┐Combining new and old drugs improves survival for soft-tissue cancer patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. Findings from a multicenter clinical trial of the combination therapy, led by researchers at Columbia University Medical Center and NewYork-Presbyterian, represent the first appreciable improvement in sarcoma outcomes in decades. … Continue reading ´╗┐Combining new and old drugs improves survival for soft-tissue cancer patients

Advertisements